04:00 PM EDT, 06/12/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Wednesday that Farxiga has received approval from the US Food and Drug Administration to improve glycaemic control in children aged 10 and older with type-2 diabetes.

Farxiga, or dapagliflozin, is an oral medication, taken once daily, that acts as a sodium-glucose cotransporter 2 inhibitor, AstraZeneca ( AZN ) said.

The FDA approval was based on positive outcomes from a phase 3 trial, which assessed dapagliflozin's effectiveness and safety as an add-on treatment for children and adolescents with T2D receiving metformin, insulin, or both, the company said.

AstraZeneca ( AZN ) shares were up nearly 1% in recent trading.

Price: 79.95, Change: +0.72, Percent Change: +0.91